Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Phase 1 Terminated 52 enrolled Exelixis

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a Phase 1, open-label, dose-escalation and expansion study evaluating the safety, tolerability, PK, antitumor activity, and effect on biomarkers of XL102 administered orally alone and in multiple combination regimens to subjects with advanced solid tumors.

Timeline

Start: 2021-02-10
Primary completion: 2024-05-02
Completion: 2024-05-02

Publications

Gaur T, Poddutoori R, Khare L, Bagal B, Rashmi S, Patkar N, Tembhare P, Pg S, Shetty D, Dutt A, Zhang Q, Konopleva M, Platzbeckar U, Gupta S, Samajdar S, Ramchandra M, Khattry N, Hasan SK. Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax. J Exp Clin Cancer Res. 2023 Jul 29;42(1):186. doi: 10.1186/s13046-023-02750-w.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	XL102	Unknown	20 mg	Oral
Subject	XL102	Unknown	40 mg	Oral
Background	Abiraterone acetate	Small molecule	1000 mg	Oral
Background	Fulvestrant	Small molecule	500 mg	Intramuscular
Background	Prednisone	Other / unclassified	5 mg	Oral

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Summary

Timeline

Publications

Drugs

Indications